VolitionRx Limited to Present at Conferences in March 2021
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil falls on weaker demand outlook and higher US stocks
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Cantor Fitzgerald Starts VolitionRX (VNRX) at Overweight
March 9, 2021 4:08 PM ESTCantor Fitzgerald analyst Kyle Mikson initiates coverage on VolitionRX (NYSE: VNRX) with a Overweight rating and a price target of $8.00.
The analyst comments "We are initiating coverage of VolitionRx (VNRX) with an Overweight rating and a 12-month price target of $8. The company is developing a suite of blood-based (liquid... More
